Industry
Biotechnology
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Loading...
Open
1.99
Mkt cap
105M
Volume
775K
High
2.03
P/E Ratio
-1.96
52-wk high
3.52
Low
1.75
Div yield
N/A
52-wk low
1.12
Portfolio Pulse from Benzinga Newsdesk
October 14, 2024 | 10:19 am
Portfolio Pulse from Benzinga Newsdesk
September 06, 2024 | 11:04 am
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 5:36 pm
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 12:47 pm
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:45 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 5:41 pm
Portfolio Pulse from Benzinga Newsdesk
May 30, 2024 | 11:13 am
Portfolio Pulse from Benzinga Newsdesk
May 29, 2024 | 11:05 am
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 11:52 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.